For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
ab108653 is for the quantitative determination of the Cancer Antigen CA125 concentration in human serum.
Cancer Antigen 125 (CA125) is a surface antigen associated with epithelial ovarian cancer. In serum, CA125 is associated with a high molecular weight glycoprotein. Published studies have indicated that elevated serum CA125 levels can be found in individuals with serious endometroid, clear-cell and undifferentiated ovarian carcinoma.
The serum CA125 concentration is greater than 35 units per ml in 60% of women with ovarian cancer and >80% of patients with disseminated ovarian cancer. The serum CA125 is elevated in 1% of normal healthy women, 3% of normal healthy women with benign ovarian diseases, and 6% of patients with non-neoplastic conditions (including but not limited to first trimester pregnancy, menstruation, endometriosis, uterine fibrosis, acute salphingitis, hepatic diseases and inflammation of peritoneum, pericardium or pleura). Serum CA125 concentration may be useful in monitoring treatment and distinguishing between good response to treatment and progressive malignant disease with poor therapeutic response. To date, CA125 is the most sensitive marker for residual epithelial ovarian cancer.
|Components||1 x 96 tests|
|20X Washing Solution||1 x 50ml|
|CA125 Reference Standard 0 (1 ml, 0 U/ml)||1 x 1ml|
|CA125 Reference Standard 1 (1 ml, 15 U/ml)||1 x 1ml|
|CA125 Reference Standard 2 (1 ml, 50 U/ml)||1 x 1ml|
|CA125 Reference Standard 3 (1 ml, 100 U/ml)||1 x 1ml|
|CA125 Reference Standard 4 (1 ml, 200 U/ml)||1 x 1ml|
|CA125 Reference Standard 5 (1 ml, 400 U/ml)||1 x 1ml|
|Enzyme Conjugate Reagent||1 x 13ml|
|Murine Monoclonal anti-CA125 coated microtiter plate||1 unit|
|Stop Solution||1 x 11ml|
|TMB Substrate Solution||1 x 11ml|
Our Abpromise guarantee covers the use of ab108653 in the following tested applications.
|ELISA||Use at an assay dependent dilution.|
ab108653 has not yet been referenced specifically in any publications.